Article
BRET-based self-cleaving biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery
2021-07-28
Abstract excerpt
The 3C-like protease (3CLpro) of SARS-CoV-2 is an attractive drug target for developing antivirals against SARS-CoV-2. A few small molecule inhibitors of 3CLpro are in clinical trials for COVID-19 treatments and more inhibitors are being developed. One limiting factor for 3CLpro inhibitors development is that the cellular activities of such inhibitors have to be evaluated in a Biosafety Level 3 (BSL-3) or BSL-4 la...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0c7cebab-7c08-51f4-89e9-61a75c6e9a71
- DOI
- 10.1101/2021.07.28.454072
